Impact of COVID-19 Outbreak on Vector-Based RNAi, Global Market Research Report 2020
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Vector-Based RNAi market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Vector-Based RNAi industry.
Segment by Type, the Vector-Based RNAi market is segmented into
The Vector-Based RNAi market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Vector-Based RNAi market report are:
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Vector-Based RNAi market include:
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Vector-Based RNAi market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Vector-Based RNAi industry.
Segment by Type, the Vector-Based RNAi market is segmented into
- siRNA Design
- siRNA Vectors
- Custom siRNA Construction
- Hospitals
- Speciality Clinics
The Vector-Based RNAi market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Vector-Based RNAi market report are:
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Vector-Based RNAi market include:
- Merck & Co.
- Phio Pharmaceutical
- Quark Pharmaceuticals
- Thermo Fisher Scientific
- Silence Therapeutics
- Qiagen NV
- Ionis Pharmaceutical
- Dicerna Pharmaceuticals
- Arrowhead Pharmaceuticals
- Arcturus Therapeutics
- Alnylam Pharmaceuticals
1 VECTOR-BASED RNAI MARKET OVERVIEW
1.1 Product Overview and Scope of Vector-Based RNAi
1.2 Covid-19 Impact on Vector-Based RNAi Segment by Type
1.2.1 Global Vector-Based RNAi Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 siRNA Design
1.2.3 siRNA Vectors
1.2.4 Custom siRNA Construction
1.3 Covid-19 Impact on Vector-Based RNAi Segment by Application
1.3.1 Vector-Based RNAi Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Speciality Clinics
1.4 Covid-19 Impact on Global Vector-Based RNAi Market Size Estimates and Forecasts
1.4.1 Global Vector-Based RNAi Revenue 2015-2026
1.4.2 Global Vector-Based RNAi Sales 2015-2026
1.4.3 Vector-Based RNAi Market Size by Region: 2020 Versus 2026
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Vector-Based RNAi Industry
1.7 COVID-19 Impact: Vector-Based RNAi Market Trends
2 COVID-19 IMPACT ON GLOBAL VECTOR-BASED RNAI MARKET COMPETITION BY MANUFACTURERS
2.1 Global Vector-Based RNAi Sales Market Share by Manufacturers (2015-2020)
2.2 Global Vector-Based RNAi Revenue Share by Manufacturers (2015-2020)
2.3 Global Vector-Based RNAi Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Vector-Based RNAi Manufacturing Sites, Area Served, Product Type
2.5 Vector-Based RNAi Market Competitive Situation and Trends
2.5.1 Vector-Based RNAi Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Vector-Based RNAi Players (Opinion Leaders)
3 COVID-19 IMPACT ON VECTOR-BASED RNAI RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Vector-Based RNAi Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Vector-Based RNAi Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Vector-Based RNAi Market Facts & Figures by Country
3.3.1 North America Vector-Based RNAi Sales by Country
3.3.2 North America Vector-Based RNAi Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Vector-Based RNAi Market Facts & Figures by Country
3.4.1 Europe Vector-Based RNAi Sales by Country
3.4.2 Europe Vector-Based RNAi Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Vector-Based RNAi Market Facts & Figures by Region
3.5.1 Asia Pacific Vector-Based RNAi Sales by Region
3.5.2 Asia Pacific Vector-Based RNAi Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Vector-Based RNAi Market Facts & Figures by Country
3.6.1 Latin America Vector-Based RNAi Sales by Country
3.6.2 Latin America Vector-Based RNAi Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Vector-Based RNAi Market Facts & Figures by Country
3.7.1 Middle East and Africa Vector-Based RNAi Sales by Country
3.7.2 Middle East and Africa Vector-Based RNAi Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 COVID-19 IMPACT ON GLOBAL VECTOR-BASED RNAI HISTORIC MARKET ANALYSIS BY TYPE
4.1 Global Vector-Based RNAi Sales Market Share by Type (2015-2020)
4.2 Global Vector-Based RNAi Revenue Market Share by Type (2015-2020)
4.3 Global Vector-Based RNAi Price Market Share by Type (2015-2020)
4.4 Global Vector-Based RNAi Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 COVID-19 IMPACT ON GLOBAL VECTOR-BASED RNAI HISTORIC MARKET ANALYSIS BY APPLICATION
5.1 Global Vector-Based RNAi Sales Market Share by Application (2015-2020)
5.2 Global Vector-Based RNAi Revenue Market Share by Application (2015-2020)
5.3 Global Vector-Based RNAi Price by Application (2015-2020)
6 COMPANY PROFILES AND KEY FIGURES IN VECTOR-BASED RNAI BUSINESS
6.1 Merck & Co.
6.1.1 Corporation Information
6.1.2 Merck & Co. Description, Business Overview and Total Revenue
6.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Merck & Co. Products Offered
6.1.5 Merck & Co. Recent Development and Response to COVID-19
6.2 Phio Pharmaceutical
6.2.1 Phio Pharmaceutical Corporation Information
6.2.2 Phio Pharmaceutical Description, Business Overview and Total Revenue
6.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Phio Pharmaceutical Products Offered
6.2.5 Phio Pharmaceutical Recent Development and Response to COVID-19
6.3 Quark Pharmaceuticals
6.3.1 Quark Pharmaceuticals Corporation Information
6.3.2 Quark Pharmaceuticals Description, Business Overview and Total Revenue
6.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Quark Pharmaceuticals Products Offered
6.3.5 Quark Pharmaceuticals Recent Development and Response to COVID-19
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue
6.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Thermo Fisher Scientific Products Offered
6.4.5 Thermo Fisher Scientific Recent Development and Response to COVID-19
6.5 Silence Therapeutics
6.5.1 Silence Therapeutics Corporation Information
6.5.2 Silence Therapeutics Description, Business Overview and Total Revenue
6.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Silence Therapeutics Products Offered
6.5.5 Silence Therapeutics Recent Development and Response to COVID-19
6.6 Qiagen NV
6.6.1 Qiagen NV Corporation Information
6.6.2 Qiagen NV Description, Business Overview and Total Revenue
6.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Qiagen NV Products Offered
6.6.5 Qiagen NV Recent Development and Response to COVID-19
6.7 Ionis Pharmaceutical
6.6.1 Ionis Pharmaceutical Corporation Information
6.6.2 Ionis Pharmaceutical Description, Business Overview and Total Revenue
6.6.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Ionis Pharmaceutical Products Offered
6.7.5 Ionis Pharmaceutical Recent Development and Response to COVID-19
6.8 Dicerna Pharmaceuticals
6.8.1 Dicerna Pharmaceuticals Corporation Information
6.8.2 Dicerna Pharmaceuticals Description, Business Overview and Total Revenue
6.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Dicerna Pharmaceuticals Products Offered
6.8.5 Dicerna Pharmaceuticals Recent Development and Response to COVID-19
6.9 Arrowhead Pharmaceuticals
6.9.1 Arrowhead Pharmaceuticals Corporation Information
6.9.2 Arrowhead Pharmaceuticals Description, Business Overview and Total Revenue
6.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Arrowhead Pharmaceuticals Products Offered
6.9.5 Arrowhead Pharmaceuticals Recent Development and Response to COVID-19
6.10 Arcturus Therapeutics
6.10.1 Arcturus Therapeutics Corporation Information
6.10.2 Arcturus Therapeutics Description, Business Overview and Total Revenue
6.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Arcturus Therapeutics Products Offered
6.10.5 Arcturus Therapeutics Recent Development and Response to COVID-19
6.11 Alnylam Pharmaceuticals
6.11.1 Alnylam Pharmaceuticals Corporation Information
6.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Description, Business Overview and Total Revenue
6.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.11.4 Alnylam Pharmaceuticals Products Offered
6.11.5 Alnylam Pharmaceuticals Recent Development and Response to COVID-19
7 VECTOR-BASED RNAI MANUFACTURING COST ANALYSIS
7.1 Vector-Based RNAi Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Vector-Based RNAi
7.4 Vector-Based RNAi Industrial Chain Analysis
8 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS
8.1 Marketing Channel
8.2 Vector-Based RNAi Distributors List
8.3 Vector-Based RNAi Customers
9 MARKET DYNAMICS
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 GLOBAL MARKET FORECAST
10.1 Global Vector-Based RNAi Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Vector-Based RNAi by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Vector-Based RNAi by Type (2021-2026)
10.2 Vector-Based RNAi Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Vector-Based RNAi by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Vector-Based RNAi by Application (2021-2026)
10.3 Vector-Based RNAi Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Vector-Based RNAi by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Vector-Based RNAi by Region (2021-2026)
10.4 North America Vector-Based RNAi Estimates and Projections (2021-2026)
10.5 Europe Vector-Based RNAi Estimates and Projections (2021-2026)
10.6 Asia Pacific Vector-Based RNAi Estimates and Projections (2021-2026)
10.7 Latin America Vector-Based RNAi Estimates and Projections (2021-2026)
10.8 Middle East and Africa Vector-Based RNAi Estimates and Projections (2021-2026)
11 RESEARCH FINDING AND CONCLUSION
12 METHODOLOGY AND DATA SOURCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
1.1 Product Overview and Scope of Vector-Based RNAi
1.2 Covid-19 Impact on Vector-Based RNAi Segment by Type
1.2.1 Global Vector-Based RNAi Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 siRNA Design
1.2.3 siRNA Vectors
1.2.4 Custom siRNA Construction
1.3 Covid-19 Impact on Vector-Based RNAi Segment by Application
1.3.1 Vector-Based RNAi Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Speciality Clinics
1.4 Covid-19 Impact on Global Vector-Based RNAi Market Size Estimates and Forecasts
1.4.1 Global Vector-Based RNAi Revenue 2015-2026
1.4.2 Global Vector-Based RNAi Sales 2015-2026
1.4.3 Vector-Based RNAi Market Size by Region: 2020 Versus 2026
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Vector-Based RNAi Industry
1.7 COVID-19 Impact: Vector-Based RNAi Market Trends
2 COVID-19 IMPACT ON GLOBAL VECTOR-BASED RNAI MARKET COMPETITION BY MANUFACTURERS
2.1 Global Vector-Based RNAi Sales Market Share by Manufacturers (2015-2020)
2.2 Global Vector-Based RNAi Revenue Share by Manufacturers (2015-2020)
2.3 Global Vector-Based RNAi Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Vector-Based RNAi Manufacturing Sites, Area Served, Product Type
2.5 Vector-Based RNAi Market Competitive Situation and Trends
2.5.1 Vector-Based RNAi Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Vector-Based RNAi Players (Opinion Leaders)
3 COVID-19 IMPACT ON VECTOR-BASED RNAI RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Vector-Based RNAi Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Vector-Based RNAi Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Vector-Based RNAi Market Facts & Figures by Country
3.3.1 North America Vector-Based RNAi Sales by Country
3.3.2 North America Vector-Based RNAi Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Vector-Based RNAi Market Facts & Figures by Country
3.4.1 Europe Vector-Based RNAi Sales by Country
3.4.2 Europe Vector-Based RNAi Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Vector-Based RNAi Market Facts & Figures by Region
3.5.1 Asia Pacific Vector-Based RNAi Sales by Region
3.5.2 Asia Pacific Vector-Based RNAi Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Vector-Based RNAi Market Facts & Figures by Country
3.6.1 Latin America Vector-Based RNAi Sales by Country
3.6.2 Latin America Vector-Based RNAi Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Vector-Based RNAi Market Facts & Figures by Country
3.7.1 Middle East and Africa Vector-Based RNAi Sales by Country
3.7.2 Middle East and Africa Vector-Based RNAi Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 COVID-19 IMPACT ON GLOBAL VECTOR-BASED RNAI HISTORIC MARKET ANALYSIS BY TYPE
4.1 Global Vector-Based RNAi Sales Market Share by Type (2015-2020)
4.2 Global Vector-Based RNAi Revenue Market Share by Type (2015-2020)
4.3 Global Vector-Based RNAi Price Market Share by Type (2015-2020)
4.4 Global Vector-Based RNAi Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 COVID-19 IMPACT ON GLOBAL VECTOR-BASED RNAI HISTORIC MARKET ANALYSIS BY APPLICATION
5.1 Global Vector-Based RNAi Sales Market Share by Application (2015-2020)
5.2 Global Vector-Based RNAi Revenue Market Share by Application (2015-2020)
5.3 Global Vector-Based RNAi Price by Application (2015-2020)
6 COMPANY PROFILES AND KEY FIGURES IN VECTOR-BASED RNAI BUSINESS
6.1 Merck & Co.
6.1.1 Corporation Information
6.1.2 Merck & Co. Description, Business Overview and Total Revenue
6.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Merck & Co. Products Offered
6.1.5 Merck & Co. Recent Development and Response to COVID-19
6.2 Phio Pharmaceutical
6.2.1 Phio Pharmaceutical Corporation Information
6.2.2 Phio Pharmaceutical Description, Business Overview and Total Revenue
6.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Phio Pharmaceutical Products Offered
6.2.5 Phio Pharmaceutical Recent Development and Response to COVID-19
6.3 Quark Pharmaceuticals
6.3.1 Quark Pharmaceuticals Corporation Information
6.3.2 Quark Pharmaceuticals Description, Business Overview and Total Revenue
6.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Quark Pharmaceuticals Products Offered
6.3.5 Quark Pharmaceuticals Recent Development and Response to COVID-19
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue
6.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Thermo Fisher Scientific Products Offered
6.4.5 Thermo Fisher Scientific Recent Development and Response to COVID-19
6.5 Silence Therapeutics
6.5.1 Silence Therapeutics Corporation Information
6.5.2 Silence Therapeutics Description, Business Overview and Total Revenue
6.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Silence Therapeutics Products Offered
6.5.5 Silence Therapeutics Recent Development and Response to COVID-19
6.6 Qiagen NV
6.6.1 Qiagen NV Corporation Information
6.6.2 Qiagen NV Description, Business Overview and Total Revenue
6.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Qiagen NV Products Offered
6.6.5 Qiagen NV Recent Development and Response to COVID-19
6.7 Ionis Pharmaceutical
6.6.1 Ionis Pharmaceutical Corporation Information
6.6.2 Ionis Pharmaceutical Description, Business Overview and Total Revenue
6.6.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Ionis Pharmaceutical Products Offered
6.7.5 Ionis Pharmaceutical Recent Development and Response to COVID-19
6.8 Dicerna Pharmaceuticals
6.8.1 Dicerna Pharmaceuticals Corporation Information
6.8.2 Dicerna Pharmaceuticals Description, Business Overview and Total Revenue
6.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Dicerna Pharmaceuticals Products Offered
6.8.5 Dicerna Pharmaceuticals Recent Development and Response to COVID-19
6.9 Arrowhead Pharmaceuticals
6.9.1 Arrowhead Pharmaceuticals Corporation Information
6.9.2 Arrowhead Pharmaceuticals Description, Business Overview and Total Revenue
6.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Arrowhead Pharmaceuticals Products Offered
6.9.5 Arrowhead Pharmaceuticals Recent Development and Response to COVID-19
6.10 Arcturus Therapeutics
6.10.1 Arcturus Therapeutics Corporation Information
6.10.2 Arcturus Therapeutics Description, Business Overview and Total Revenue
6.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Arcturus Therapeutics Products Offered
6.10.5 Arcturus Therapeutics Recent Development and Response to COVID-19
6.11 Alnylam Pharmaceuticals
6.11.1 Alnylam Pharmaceuticals Corporation Information
6.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Description, Business Overview and Total Revenue
6.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2015-2020)
6.11.4 Alnylam Pharmaceuticals Products Offered
6.11.5 Alnylam Pharmaceuticals Recent Development and Response to COVID-19
7 VECTOR-BASED RNAI MANUFACTURING COST ANALYSIS
7.1 Vector-Based RNAi Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Vector-Based RNAi
7.4 Vector-Based RNAi Industrial Chain Analysis
8 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS
8.1 Marketing Channel
8.2 Vector-Based RNAi Distributors List
8.3 Vector-Based RNAi Customers
9 MARKET DYNAMICS
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 GLOBAL MARKET FORECAST
10.1 Global Vector-Based RNAi Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Vector-Based RNAi by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Vector-Based RNAi by Type (2021-2026)
10.2 Vector-Based RNAi Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Vector-Based RNAi by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Vector-Based RNAi by Application (2021-2026)
10.3 Vector-Based RNAi Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Vector-Based RNAi by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Vector-Based RNAi by Region (2021-2026)
10.4 North America Vector-Based RNAi Estimates and Projections (2021-2026)
10.5 Europe Vector-Based RNAi Estimates and Projections (2021-2026)
10.6 Asia Pacific Vector-Based RNAi Estimates and Projections (2021-2026)
10.7 Latin America Vector-Based RNAi Estimates and Projections (2021-2026)
10.8 Middle East and Africa Vector-Based RNAi Estimates and Projections (2021-2026)
11 RESEARCH FINDING AND CONCLUSION
12 METHODOLOGY AND DATA SOURCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
LIST OF TABLES
Table 1. Global Vector-Based RNAi Sales (K Units) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Vector-Based RNAi Sales (K Units) Comparison by Application: 2020 VS 2026
Table 3. Global Vector-Based RNAi Market Size by Type (K Units) (US$ Million) (2020 VS 2026)
Table 4. COVID-19 Impact Global Market: (Four Vector-Based RNAi Market Size Forecast Scenarios)
Table 5. Opportunities and Trends for Vector-Based RNAi Players in the COVID-19 Landscape
Table 6. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 7. Key Regions/Countries Measures against Covid-19 Impact
Table 8. Proposal for Vector-Based RNAi Players to Combat Covid-19 Impact
Table 9. Global Key Vector-Based RNAi Manufacturers Covered in This Study
Table 10. Global Vector-Based RNAi Sales (K Units) by Manufacturers (2015-2020)
Table 11. Global Vector-Based RNAi Sales Share by Manufacturers (2015-2020)
Table 12. Global Vector-Based RNAi Revenue (Million USD) by Manufacturers (2015-2020)
Table 13. Global Vector-Based RNAi Revenue Share by Manufacturers (2015-2020)
Table 14. Global Market Vector-Based RNAi Average Price (US$/Unit) of Key Manufacturers (2015-2020)
Table 15. Manufacturers Vector-Based RNAi Sales Sites and Area Served
Table 16. Manufacturers Vector-Based RNAi Product Types
Table 17. Global Vector-Based RNAi Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 18. Global Vector-Based RNAi by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vector-Based RNAi as of 2019)
Table 19.Manufacturers Mergers & Acquisitions, Expansion Plans
Table 20. Main Points Interviewed from Key Vector-Based RNAi Players
Table 21. Global Vector-Based RNAi Sales (K Units) by Region (2015-2020)
Table 22. Global Vector-Based RNAi Sales Market Share by Region (2015-2020)
Table 23. Global Vector-Based RNAi Revenue (Million US$) by Region (2015-2020)
Table 24. Global Vector-Based RNAi Revenue Market Share by Region (2015-2020)
Table 25. North America Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 26. North America Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 27. North America Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 28. North America Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 29. Europe Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 30. Europe Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 31. Europe Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 32. Europe Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 33. Asia Pacific Vector-Based RNAi Sales by Region (2015-2020) (K Units)
Table 34. Asia Pacific Vector-Based RNAi Sales Market Share by Region (2015-2020)
Table 35. Asia Pacific Vector-Based RNAi Revenue by Region (2015-2020) (US$ Million)
Table 36. Asia Pacific Vector-Based RNAi Revenue Market Share by Region (2015-2020)
Table 37. Latin America Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 38. Latin America Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 39. Latin America Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 40. Latin America Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 41. Middle East and Africa Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 42. Middle East and Africa Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 43. Middle East and Africa Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 44. Middle East and Africa Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 45. Global Vector-Based RNAi Sales (K Units) by Type (2015-2020)
Table 46. Global Vector-Based RNAi Sales Share by Type (2015-2020)
Table 47. Global Vector-Based RNAi Revenue (Million US$) by Type (2015-2020)
Table 48. Global Vector-Based RNAi Revenue Share by Type (2015-2020)
Table 49. Global Vector-Based RNAi Price (US$/Unit) by Type (2015-2020)
Table 50. Global Vector-Based RNAi Sales (K Units) by Application (2015-2020)
Table 51. Global Vector-Based RNAi Sales Market Share by Application (2015-2020)
Table 52. Global Vector-Based RNAi Sales Growth Rate by Application (2015-2020)
Table 53. Merck & Co. Vector-Based RNAi Corporation Information
Table 54. Merck & Co. Description and Business Overview
Table 55. Merck & Co. Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 56. Merck & Co. Main Product
Table 57. Merck & Co. Recent Development
Table 58. Phio Pharmaceutical Vector-Based RNAi Corporation Information
Table 59. Phio Pharmaceutical Corporation Information
Table 60. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 61. Phio Pharmaceutical Main Product
Table 62. Phio Pharmaceutical Recent Development
Table 63. Quark Pharmaceuticals Vector-Based RNAi Corporation Information
Table 64. Quark Pharmaceuticals Corporation Information
Table 65. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 66. Quark Pharmaceuticals Main Product
Table 67. Quark Pharmaceuticals Recent Development
Table 68. Thermo Fisher Scientific Vector-Based RNAi Corporation Information
Table 69. Thermo Fisher Scientific Corporation Information
Table 70. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 71. Thermo Fisher Scientific Main Product
Table 72. Thermo Fisher Scientific Recent Development
Table 73. Silence Therapeutics Vector-Based RNAi Corporation Information
Table 74. Silence Therapeutics Corporation Information
Table 75. Silence Therapeutics Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 76. Silence Therapeutics Main Product
Table 77. Silence Therapeutics Recent Development
Table 78. Qiagen NV Vector-Based RNAi Corporation Information
Table 79. Qiagen NV Corporation Information
Table 80. Qiagen NV Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 81. Qiagen NV Main Product
Table 82. Qiagen NV Recent Development
Table 83. Ionis Pharmaceutical Vector-Based RNAi Corporation Information
Table 84. Ionis Pharmaceutical Corporation Information
Table 85. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 86. Ionis Pharmaceutical Main Product
Table 87. Ionis Pharmaceutical Recent Development
Table 88. Dicerna Pharmaceuticals Vector-Based RNAi Corporation Information
Table 89. Dicerna Pharmaceuticals Corporation Information
Table 90. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 91. Dicerna Pharmaceuticals Main Product
Table 92. Dicerna Pharmaceuticals Recent Development
Table 93. Arrowhead Pharmaceuticals Vector-Based RNAi Corporation Information
Table 94. Arrowhead Pharmaceuticals Corporation Information
Table 95. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 96. Arrowhead Pharmaceuticals Main Product
Table 97. Arrowhead Pharmaceuticals Recent Development
Table 98. Arcturus Therapeutics Vector-Based RNAi Corporation Information
Table 99. Arcturus Therapeutics Corporation Information
Table 100. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 101. Arcturus Therapeutics Main Product
Table 102. Arcturus Therapeutics Recent Development
Table 103. Alnylam Pharmaceuticals Vector-Based RNAi Corporation Information
Table 104. Alnylam Pharmaceuticals Corporation Information
Table 105. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 106. Alnylam Pharmaceuticals Main Product
Table 107. Alnylam Pharmaceuticals Recent Development
Table 108. Sales Base and Market Concentration Rate of Raw Material
Table 109. Key Suppliers of Raw Materials
Table 110. Vector-Based RNAi Distributors List
Table 111. Vector-Based RNAi Customers List
Table 112. Market Key Trends
Table 113. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 114. Key Challenges
Table 115. Global Vector-Based RNAi Sales (K Units) Forecast by Type (2021-2026)
Table 116. Global Vector-Based RNAi Sales Market Share Forecast by Type (2021-2026)
Table 117. Global Vector-Based RNAi Revenue (Million US$) Forecast by Type (2021-2026)
Table 118. Global Vector-Based RNAi Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 119. Global Vector-Based RNAi Sales (K Units) Forecast by Application (2021-2026)
Table 120. Global Vector-Based RNAi Revenue (Million US$) Forecast by Application (2021-2026)
Table 121. Global Vector-Based RNAi Sales (K Units) Forecast by Region (2021-2026)
Table 122. Global Vector-Based RNAi Sales Market Share Forecast by Region (2021-2026)
Table 123. Global Vector-Based RNAi Revenue Forecast by Region (2021-2026) (US$ Million)
Table 124. Global Vector-Based RNAi Revenue Market Share Forecast by Region (2021-2026)
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 1. Global Vector-Based RNAi Sales (K Units) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Vector-Based RNAi Sales (K Units) Comparison by Application: 2020 VS 2026
Table 3. Global Vector-Based RNAi Market Size by Type (K Units) (US$ Million) (2020 VS 2026)
Table 4. COVID-19 Impact Global Market: (Four Vector-Based RNAi Market Size Forecast Scenarios)
Table 5. Opportunities and Trends for Vector-Based RNAi Players in the COVID-19 Landscape
Table 6. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 7. Key Regions/Countries Measures against Covid-19 Impact
Table 8. Proposal for Vector-Based RNAi Players to Combat Covid-19 Impact
Table 9. Global Key Vector-Based RNAi Manufacturers Covered in This Study
Table 10. Global Vector-Based RNAi Sales (K Units) by Manufacturers (2015-2020)
Table 11. Global Vector-Based RNAi Sales Share by Manufacturers (2015-2020)
Table 12. Global Vector-Based RNAi Revenue (Million USD) by Manufacturers (2015-2020)
Table 13. Global Vector-Based RNAi Revenue Share by Manufacturers (2015-2020)
Table 14. Global Market Vector-Based RNAi Average Price (US$/Unit) of Key Manufacturers (2015-2020)
Table 15. Manufacturers Vector-Based RNAi Sales Sites and Area Served
Table 16. Manufacturers Vector-Based RNAi Product Types
Table 17. Global Vector-Based RNAi Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 18. Global Vector-Based RNAi by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vector-Based RNAi as of 2019)
Table 19.Manufacturers Mergers & Acquisitions, Expansion Plans
Table 20. Main Points Interviewed from Key Vector-Based RNAi Players
Table 21. Global Vector-Based RNAi Sales (K Units) by Region (2015-2020)
Table 22. Global Vector-Based RNAi Sales Market Share by Region (2015-2020)
Table 23. Global Vector-Based RNAi Revenue (Million US$) by Region (2015-2020)
Table 24. Global Vector-Based RNAi Revenue Market Share by Region (2015-2020)
Table 25. North America Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 26. North America Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 27. North America Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 28. North America Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 29. Europe Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 30. Europe Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 31. Europe Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 32. Europe Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 33. Asia Pacific Vector-Based RNAi Sales by Region (2015-2020) (K Units)
Table 34. Asia Pacific Vector-Based RNAi Sales Market Share by Region (2015-2020)
Table 35. Asia Pacific Vector-Based RNAi Revenue by Region (2015-2020) (US$ Million)
Table 36. Asia Pacific Vector-Based RNAi Revenue Market Share by Region (2015-2020)
Table 37. Latin America Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 38. Latin America Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 39. Latin America Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 40. Latin America Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 41. Middle East and Africa Vector-Based RNAi Sales by Country (2015-2020) (K Units)
Table 42. Middle East and Africa Vector-Based RNAi Sales Market Share by Country (2015-2020)
Table 43. Middle East and Africa Vector-Based RNAi Revenue by Country (2015-2020) (US$ Million)
Table 44. Middle East and Africa Vector-Based RNAi Revenue Market Share by Country (2015-2020)
Table 45. Global Vector-Based RNAi Sales (K Units) by Type (2015-2020)
Table 46. Global Vector-Based RNAi Sales Share by Type (2015-2020)
Table 47. Global Vector-Based RNAi Revenue (Million US$) by Type (2015-2020)
Table 48. Global Vector-Based RNAi Revenue Share by Type (2015-2020)
Table 49. Global Vector-Based RNAi Price (US$/Unit) by Type (2015-2020)
Table 50. Global Vector-Based RNAi Sales (K Units) by Application (2015-2020)
Table 51. Global Vector-Based RNAi Sales Market Share by Application (2015-2020)
Table 52. Global Vector-Based RNAi Sales Growth Rate by Application (2015-2020)
Table 53. Merck & Co. Vector-Based RNAi Corporation Information
Table 54. Merck & Co. Description and Business Overview
Table 55. Merck & Co. Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 56. Merck & Co. Main Product
Table 57. Merck & Co. Recent Development
Table 58. Phio Pharmaceutical Vector-Based RNAi Corporation Information
Table 59. Phio Pharmaceutical Corporation Information
Table 60. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 61. Phio Pharmaceutical Main Product
Table 62. Phio Pharmaceutical Recent Development
Table 63. Quark Pharmaceuticals Vector-Based RNAi Corporation Information
Table 64. Quark Pharmaceuticals Corporation Information
Table 65. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 66. Quark Pharmaceuticals Main Product
Table 67. Quark Pharmaceuticals Recent Development
Table 68. Thermo Fisher Scientific Vector-Based RNAi Corporation Information
Table 69. Thermo Fisher Scientific Corporation Information
Table 70. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 71. Thermo Fisher Scientific Main Product
Table 72. Thermo Fisher Scientific Recent Development
Table 73. Silence Therapeutics Vector-Based RNAi Corporation Information
Table 74. Silence Therapeutics Corporation Information
Table 75. Silence Therapeutics Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 76. Silence Therapeutics Main Product
Table 77. Silence Therapeutics Recent Development
Table 78. Qiagen NV Vector-Based RNAi Corporation Information
Table 79. Qiagen NV Corporation Information
Table 80. Qiagen NV Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 81. Qiagen NV Main Product
Table 82. Qiagen NV Recent Development
Table 83. Ionis Pharmaceutical Vector-Based RNAi Corporation Information
Table 84. Ionis Pharmaceutical Corporation Information
Table 85. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 86. Ionis Pharmaceutical Main Product
Table 87. Ionis Pharmaceutical Recent Development
Table 88. Dicerna Pharmaceuticals Vector-Based RNAi Corporation Information
Table 89. Dicerna Pharmaceuticals Corporation Information
Table 90. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 91. Dicerna Pharmaceuticals Main Product
Table 92. Dicerna Pharmaceuticals Recent Development
Table 93. Arrowhead Pharmaceuticals Vector-Based RNAi Corporation Information
Table 94. Arrowhead Pharmaceuticals Corporation Information
Table 95. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 96. Arrowhead Pharmaceuticals Main Product
Table 97. Arrowhead Pharmaceuticals Recent Development
Table 98. Arcturus Therapeutics Vector-Based RNAi Corporation Information
Table 99. Arcturus Therapeutics Corporation Information
Table 100. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 101. Arcturus Therapeutics Main Product
Table 102. Arcturus Therapeutics Recent Development
Table 103. Alnylam Pharmaceuticals Vector-Based RNAi Corporation Information
Table 104. Alnylam Pharmaceuticals Corporation Information
Table 105. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 106. Alnylam Pharmaceuticals Main Product
Table 107. Alnylam Pharmaceuticals Recent Development
Table 108. Sales Base and Market Concentration Rate of Raw Material
Table 109. Key Suppliers of Raw Materials
Table 110. Vector-Based RNAi Distributors List
Table 111. Vector-Based RNAi Customers List
Table 112. Market Key Trends
Table 113. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 114. Key Challenges
Table 115. Global Vector-Based RNAi Sales (K Units) Forecast by Type (2021-2026)
Table 116. Global Vector-Based RNAi Sales Market Share Forecast by Type (2021-2026)
Table 117. Global Vector-Based RNAi Revenue (Million US$) Forecast by Type (2021-2026)
Table 118. Global Vector-Based RNAi Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 119. Global Vector-Based RNAi Sales (K Units) Forecast by Application (2021-2026)
Table 120. Global Vector-Based RNAi Revenue (Million US$) Forecast by Application (2021-2026)
Table 121. Global Vector-Based RNAi Sales (K Units) Forecast by Region (2021-2026)
Table 122. Global Vector-Based RNAi Sales Market Share Forecast by Region (2021-2026)
Table 123. Global Vector-Based RNAi Revenue Forecast by Region (2021-2026) (US$ Million)
Table 124. Global Vector-Based RNAi Revenue Market Share Forecast by Region (2021-2026)
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Picture of Vector-Based RNAi
Figure 2. Global Vector-Based RNAi Sales Market Share by Type: 2020 VS 2026
Figure 3. siRNA Design Product Picture
Figure 4. siRNA Vectors Product Picture
Figure 5. Custom siRNA Construction Product Picture
Figure 6. Global Vector-Based RNAi Consumption Market Share by Application: 2020 VS 2026
Figure 7. Hospitals
Figure 8. Speciality Clinics
Figure 9. Global Vector-Based RNAi Market Size 2015-2026 (US$ Million)
Figure 10. Global Vector-Based RNAi Sales Capacity (K Units) (2015-2026)
Figure 11. Global Vector-Based RNAi Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Vector-Based RNAi Sales Share by Manufacturers in 2020
Figure 13. Global Vector-Based RNAi Revenue Share by Manufacturers in 2019
Figure 14. The Global 5 and 10 Largest Players: Market Share by Vector-Based RNAi Revenue in 2019
Figure 15. Vector-Based RNAi Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 16. Global Vector-Based RNAi Sales Market Share by Region (2015-2020)
Figure 17. Global Vector-Based RNAi Sales Market Share by Region in 2019
Figure 18. Global Vector-Based RNAi Revenue Market Share by Region (2015-2020)
Figure 19. Global Vector-Based RNAi Revenue Market Share by Region in 2019
Figure 20. North America Vector-Based RNAi Sales Market Share by Country in 2019
Figure 21. North America Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 22. U.S. Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 23. U.S. Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 24. Canada Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 25. Canada Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 26. Europe Vector-Based RNAi Sales Market Share by Country in 2019
Figure 27. Europe Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 28. Germany Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 29. Germany Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 30. France Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 31. France Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 32. U.K. Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 33. U.K. Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Italy Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 35. Italy Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Russia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 37. Russia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Asia Pacific Vector-Based RNAi Sales Market Share by Region in 2019
Figure 39. Asia Pacific Vector-Based RNAi Revenue Market Share by Region in 2019
Figure 40. China Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 41. China Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Japan Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 43. Japan Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. South Korea Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 45. South Korea Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. India Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 47. India Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Australia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 49. Australia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Taiwan Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 51. Taiwan Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Indonesia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 53. Indonesia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Thailand Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 55. Thailand Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Malaysia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 57. Malaysia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Philippines Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 59. Philippines Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Vietnam Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 61. Vietnam Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Latin America Vector-Based RNAi Sales Market Share by Country in 2019
Figure 63. Latin America Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 64. Mexico Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 65. Mexico Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Brazil Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 67. Brazil Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Argentina Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 69. Argentina Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Middle East and Africa Vector-Based RNAi Sales Market Share by Country in 2019
Figure 71. Middle East and Africa Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 72. Turkey Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 73. Turkey Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Saudi Arabia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 75. Saudi Arabia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. U.A.E Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 77. U.A.E Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Sales Market Share of Vector-Based RNAi by Type (2015-2020)
Figure 79. Sales Market Share of Vector-Based RNAi by Type in 2019
Figure 80. Revenue Share of Vector-Based RNAi by Type (2015-2020)
Figure 81. Revenue Market Share of Vector-Based RNAi by Type in 2019
Figure 82. Global Vector-Based RNAi Sales Growth by Type (2015-2020) (K Units)
Figure 83. Global Vector-Based RNAi Sales Market Share by Application (2015-2020)
Figure 84. Global Vector-Based RNAi Sales Market Share by Application in 2019
Figure 85. Global Revenue Share of Vector-Based RNAi by Application (2015-2020)
Figure 86. Global Revenue Share of Vector-Based RNAi by Application in 2020
Figure 87. Merck & Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 88. Phio Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 89. Quark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 90. Thermo Fisher Scientific Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Silence Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Qiagen NV Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. Ionis Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. Dicerna Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. Arrowhead Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 96. Arcturus Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 97. Alnylam Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 98. Price Trend of Key Raw Materials
Figure 99. Manufacturing Cost Structure of Vector-Based RNAi
Figure 100. Manufacturing Process Analysis of Vector-Based RNAi
Figure 101. Vector-Based RNAi Industrial Chain Analysis
Figure 102. Channels of Distribution
Figure 103. Distributors Profiles
Figure 104. Porter's Five Forces Analysis
Figure 105. North America Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 106. North America Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 107. Europe Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 108. Europe Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 109. Latin America Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 110. Latin America Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 111. Middle East and Africa Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 112. Middle East and Africa Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 113. Asia Pacific Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 114. Asia Pacific Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 115. Bottom-up and Top-down Approaches for This Report
Figure 116. Data Triangulation
Figure 117. Key Executives Interviewed
Figure 1. Picture of Vector-Based RNAi
Figure 2. Global Vector-Based RNAi Sales Market Share by Type: 2020 VS 2026
Figure 3. siRNA Design Product Picture
Figure 4. siRNA Vectors Product Picture
Figure 5. Custom siRNA Construction Product Picture
Figure 6. Global Vector-Based RNAi Consumption Market Share by Application: 2020 VS 2026
Figure 7. Hospitals
Figure 8. Speciality Clinics
Figure 9. Global Vector-Based RNAi Market Size 2015-2026 (US$ Million)
Figure 10. Global Vector-Based RNAi Sales Capacity (K Units) (2015-2026)
Figure 11. Global Vector-Based RNAi Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Vector-Based RNAi Sales Share by Manufacturers in 2020
Figure 13. Global Vector-Based RNAi Revenue Share by Manufacturers in 2019
Figure 14. The Global 5 and 10 Largest Players: Market Share by Vector-Based RNAi Revenue in 2019
Figure 15. Vector-Based RNAi Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 16. Global Vector-Based RNAi Sales Market Share by Region (2015-2020)
Figure 17. Global Vector-Based RNAi Sales Market Share by Region in 2019
Figure 18. Global Vector-Based RNAi Revenue Market Share by Region (2015-2020)
Figure 19. Global Vector-Based RNAi Revenue Market Share by Region in 2019
Figure 20. North America Vector-Based RNAi Sales Market Share by Country in 2019
Figure 21. North America Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 22. U.S. Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 23. U.S. Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 24. Canada Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 25. Canada Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 26. Europe Vector-Based RNAi Sales Market Share by Country in 2019
Figure 27. Europe Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 28. Germany Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 29. Germany Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 30. France Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 31. France Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 32. U.K. Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 33. U.K. Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Italy Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 35. Italy Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Russia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 37. Russia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Asia Pacific Vector-Based RNAi Sales Market Share by Region in 2019
Figure 39. Asia Pacific Vector-Based RNAi Revenue Market Share by Region in 2019
Figure 40. China Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 41. China Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Japan Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 43. Japan Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. South Korea Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 45. South Korea Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. India Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 47. India Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Australia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 49. Australia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Taiwan Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 51. Taiwan Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Indonesia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 53. Indonesia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Thailand Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 55. Thailand Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Malaysia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 57. Malaysia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Philippines Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 59. Philippines Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Vietnam Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 61. Vietnam Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Latin America Vector-Based RNAi Sales Market Share by Country in 2019
Figure 63. Latin America Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 64. Mexico Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 65. Mexico Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Brazil Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 67. Brazil Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Argentina Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 69. Argentina Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Middle East and Africa Vector-Based RNAi Sales Market Share by Country in 2019
Figure 71. Middle East and Africa Vector-Based RNAi Revenue Market Share by Country in 2019
Figure 72. Turkey Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 73. Turkey Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Saudi Arabia Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 75. Saudi Arabia Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. U.A.E Vector-Based RNAi Sales Growth Rate (2015-2020) (K Units)
Figure 77. U.A.E Vector-Based RNAi Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Sales Market Share of Vector-Based RNAi by Type (2015-2020)
Figure 79. Sales Market Share of Vector-Based RNAi by Type in 2019
Figure 80. Revenue Share of Vector-Based RNAi by Type (2015-2020)
Figure 81. Revenue Market Share of Vector-Based RNAi by Type in 2019
Figure 82. Global Vector-Based RNAi Sales Growth by Type (2015-2020) (K Units)
Figure 83. Global Vector-Based RNAi Sales Market Share by Application (2015-2020)
Figure 84. Global Vector-Based RNAi Sales Market Share by Application in 2019
Figure 85. Global Revenue Share of Vector-Based RNAi by Application (2015-2020)
Figure 86. Global Revenue Share of Vector-Based RNAi by Application in 2020
Figure 87. Merck & Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 88. Phio Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 89. Quark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 90. Thermo Fisher Scientific Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Silence Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Qiagen NV Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. Ionis Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. Dicerna Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. Arrowhead Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 96. Arcturus Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 97. Alnylam Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 98. Price Trend of Key Raw Materials
Figure 99. Manufacturing Cost Structure of Vector-Based RNAi
Figure 100. Manufacturing Process Analysis of Vector-Based RNAi
Figure 101. Vector-Based RNAi Industrial Chain Analysis
Figure 102. Channels of Distribution
Figure 103. Distributors Profiles
Figure 104. Porter's Five Forces Analysis
Figure 105. North America Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 106. North America Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 107. Europe Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 108. Europe Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 109. Latin America Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 110. Latin America Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 111. Middle East and Africa Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 112. Middle East and Africa Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 113. Asia Pacific Vector-Based RNAi Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 114. Asia Pacific Vector-Based RNAi Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 115. Bottom-up and Top-down Approaches for This Report
Figure 116. Data Triangulation
Figure 117. Key Executives Interviewed
